Login to Your Account

Biotie Edges Up on Tozadenant Phase IIb Data in Parkinson's

Wednesday, December 12, 2012
Biotie Therapies Oyj got a final-quarter lift from its Parkinson's disease drug tozadenant (SYN115), which hit the primary endpoint of a Phase IIb trial in 420 patients.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription